Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 2,001–2,039 of 2,039
Alevizopoulos, A. G., Vasilakos, V., Kritikos, I., Alevizopoulou, M., Korompoki, E., Ψαλτοπούλου, Θ., & Paschou, S. Α. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261457548
Liu, X., & Wang, W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71373
Mahmoud, R., Yousif, A. A. Z., Osman, A. F. M., Omer, E. O. E., Talaat, A. I. A., Mohamed, O., Akasha, S. A. M., Saleh, E., & Osman, H. M. M. (2026) · Cureus · doi:10.7759/cureus.116733
Shi, Y., Yang, X., Meng, F., Feenstra, K. A., Chen, J., Gu, Z., Gao, X., Yao, W., Dong, G., Gong, L., et al. (2026) · ACS Omega · doi:10.1021/acsomega.6c05930
de Souza, P. F., Patriani, G., & Pacheco, C. M. R. (2026) · Cureus · doi:10.7759/cureus.116779
Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists
Ma, J., Feng, X., Xu, W., & Lyu, J. (2026) · Peptides · doi:10.1016/j.peptides.2026.171519
Mayne, K. J., Lee, M. M. Y., Sattar, N. A., & Herrington, W. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107193
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Kuo, C.-Y., Wu, J.-Y., Tsai, Y., Lai, C.-C., & Wang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1880132
Matson, R. P., Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · Diabetology · doi:10.3390/diabetology7100189
The American Society of Metabolic and Bariatric Surgery 2022-2024 procedural volume assessment
Northup, C. J., Albaugh, V. L., Clapp, B. L., Hollenbeak, C. S., Peterson, R. M., Morton, J. M., Samuels, J. M., Varban, O. A., & Kindel, T. L. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.09.018
Alkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
“SURPASS-2 showed greater reductions in glycated hemoglobin and body weight with tirzepatide than with semaglutide 1.0 mg in patients with T2D, but it was not designed to compare cardiovascular outcomes [48].”
InfluentialNew-Onset Heart Failure in Patients with Obesity using Tirzepatide or SemaglutidePreprint
Al-Nusair, M., Haddad, T. A., Khurana, S., & Al‐Nusair, J. (2026) · medRxiv · doi:10.64898/2026.09.21.26363546
Wu, Y., Li, K., Wang, Y., Chen, Z., Shi, M., & Zhao, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1941948
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01921-0
Efficacy and safety of tirzepatide in the treatment of obesity and obesity-associated comorbidities
Sakhnova, E. E., Gavrilova, N. A., Ostroumova, O. D., Кочетков, А. И., Telkova, S. S., & Moryakova, Y. S. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-324
Rescalli, M. B., Fagiolini, A. M., Carmellini, P., Pinzi, M., Castaldo, F., & Cuomo, A. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70066 · Cited by 1
Vikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
Pan, J., Guo, C., Huang, Q., Zhang, Y., Shen, Y., & Guo, C. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm55884
Hoog, M. M., Vallarino, C. R., Maldonado, J. M., Grabner, M., Teng, C., Terrell, K. A., & Richard, E. L. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.10.1173
Nava, A. M., & Alencar, M. A. V. D. S. D. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n64-135
Guenoun, J.-M., & Lachkar, Y. (2026) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2026.104990
Popa, E., Popa, A. E., Poroch, V., Schreiner, T. G., Slănină, A. M., Poroch, M., Hatneanu, A. M., Ungureanu, M. I., Petroaie, A. D., Bacușcă, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198738
Ilie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Stoicescu, L., Homorodean, C., Gligor, F. G., & Morgovan, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-120507
“On the other hand, despite automated duplication detection in EV, the presence of residual duplicates cannot be excluded.”
Tirzepatide: a new treatment for obesity - literature review
Correia, S., Pimenta, A. M., Souto, M. R. S., & Catarino, R. I. L. (2026) · Athena health & research journal. · doi:10.62741/ahrj.v3isuppl.2.199
Ganjre, S., Borah, L., & Khardenavis, A. (2026) · Cureus · doi:10.7759/cureus.117270
Wang, Y., Liu, Z., Wang, S., Lv, C., El-Seedi, H. R., Khalifa, S. A. M., & Wang, H. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70351
“…a phase of cardiovascular- kidney-metabolic integration and therapeutic diversification, characterized by semaglutide, the dual GIP/GLP-1 receptor agonist tirzepatide, obesity and weight loss, chronic kidney disease, fixed-ratio combinations, oral formulations and real-world evidence [25, 28–33].”
Lu, G., Wang, X., Zhuang, H., Wang, X., Zhou, X., & Zhao, G. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179387
Emerging Therapies in Diabetes: New Drugs and Innovative Remedies
bhavikkimar, P. P., Raval, A. M., Patel, H. B., Patel, K. H., Patel, P., & Prajapati, T. (2026) · Pharmacology and Toxicology Research · doi:10.68163/ptr.2026.61
李, 美., Zhou, C., & Zhou, J. (2026) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986261492895
Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes
Al-Nusair, M., Khurana, S., Eysha, M., Elchouemi, M., & Zaki, I. H. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02087-z
“The tirzepatide group had lower incidences A g e a t I nd e x , m e d i a n (I Q R ) 59 [ 18 ] 60 [ 17 ] 0 .”
Liu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
Molecular signaling networks that connect tissue dysfunction to systemic insulin resistance
Mir, R., Algehainy, N. A., Jalal, M. M., Altayar, M. A., Almotairi, R., Tayeb, F. J., Bedaiwi, R. I., Altemani, F. H., Almasoudi, K. S., Albalawi, I. A., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1952238
Eliseeva, E. M., Druzhinina, A. A., & Chistokhina, A. A. (2026) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2026-14-3-249-262
Lee, A. A., Borisov, D. О., Novikova, V. S., Kashirskikh, D. A., Khotina, V. A., Gasanov, V. A. O., & Vasiliev, A. V. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.412
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
He, Y., Ma, T., 邢邯英, Cao, X., Song, F., Pan, Y., & Luping, R. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179418
Erkan, İ. B. Ö., Senturk, L. M., Erel, C. T., Seyisoğlu, H., Şahmay, S., & Durmuşoğlu, F. (2026) · Climacteric · doi:10.1080/13697137.2026.2735765 · Cited by 1
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Franco, D. R., Kahn, S. E., Lincoff, A. M., Martins, R. F., McGuire, D. K., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag452
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.